Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Modern Age

Claya
Graded #268

Higher grade

vs+4.099999999999994
Modern Age
Graded #361

Lower grade

The verdict

Claya takes it — 62.8/100 to 58.7/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueModern Age +3
42
45
Dose & formulationClaya +22
75
53
Clinical oversightModern Age +1
82
83
Labs & monitoringModern Age +24
53
77
FulfillmentClaya +8
67
59
Contract termsClaya +41
61
20
Claya · left barModern Age · right bar

The numbers

MetricClayaModern Age
WeighScore62.8/10058.7/100
GradeCC
Scorecard rank#268#361
Semaglutide$299/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Modern Age

Graded #361 · C

Strengths

  • Uses FDA-approved branded GLP-1 medication (Wegovy/Ozempic), no compounding
  • Comprehensive assessment with labs, at-home tests and clinician review
  • Board-certified clinicians and structured 6-month program
  • Longevity-oriented, whole-person approach beyond weight loss

Where it loses points

  • Expensive: $500 assessment plus $500 program, with medication billed separately
  • Branded GLP-1 can cost $900-1600/mo if not covered by insurance
  • Only available in 16 states (specific states not listed publicly)
  • Premium positioning makes it costlier than compounded-subscription rivals

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard